(RTTNews) - ADMA Biologics, Inc. (ADMA) announced FDA Approval for the company's in-house aseptic fill-finish machine, the VanRx SA25. The company said the VanRx approval provides ADMA with internal fill-finish operations, capable of sufficiently addressing all forecasted production requirements for commercial products. The approval will also provide the company with the opportunity to onboard new fill-finish contract manufacturing opportunities with third parties.
"With the VanRx operational, we are anticipating meaningfully improved gross margins, enhanced patient supply consistency, accelerated inventory production cycle times, and increased control and visibility of commercial product lot releases, creating more predictable near-term revenue results," said Adam Grossman, CEO of ADMA.
Shares of ADMA Biologics were up 11% in pre-market trade on Wednesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
